5、消化系统肿瘤消化系统肿瘤 (12).pdf

《5、消化系统肿瘤消化系统肿瘤 (12).pdf》由会员分享，可在线阅读，更多相关《5、消化系统肿瘤消化系统肿瘤 (12).pdf（6页珍藏版）》请在得力文库 - 分享文档赚钱的网站上搜索。

1、 Journal of Clinical Oncology List of Issues Volume 39,Issue 15_suppl Meeting Abstract|2021 ASCO Annual Meeting IGASTROINTESTINAL CANCERGASTROESOPHAGEAL,PANCREATIC,ANDHEPATOBILIARYToripalimab with chemotherapy as first-linetreatment for advanced biliary tract tumors:Rights&PermissionsOPTIONS&TOOLSEx

2、port CitationTrack CitationAdd To FavoritesADVERTISEMENTADADVERTISEMENTLog InSubmitE-AlertsCartOpenAthens/Shibboleth MENU Article ToolsUpdate analytic results of an open-labelphase II clinical study(JS001-ZS-BC001).Wei Li,Yiyi Yu,Xiaojing Xu,Xi Guo,Yueqi Wang,Qian Li,.Show MoreAbstract Disclosurese1

3、6170Background:A phase II clinical study wasconducted to evaluate the safety and efficacy oftoripalimab,a novel PD-1 inhibitor,combined withchemotherapy in patients with advanced biliarytract cancers(aBTCs)(NCT03796429).Thepreliminary results indicated the combinationtreatment is well tolerable and

4、effective.Methods:Treatment naive patients with aBTCs receivedtoripalimab(240mg intravenously every threeweeks)combined with chemotherapy(gemcitabine 1000 mg/m2 d1,d8+S-1 40-60mgCOMPANION ARTICLESNo companion articlesARTICLE CITATIONDOI:10.1200/JCO.2021.39.15_suppl.e16170Journal of Clinical Oncology

5、 39,no.15_supplPublished online May 28,2021.WE RECOMMENDADVERTISEMENTEmployer:Merritt HawkinsApply for this job Employer:Potomac Oncology&HematologyApply for this job Hematology-Oncology OpportunityJust Outside of ChicagoRockford,Illinois N/AA reputable integrated health system seekinga board-certif

6、ied or board-eligiblehematologist-oncologist to join its team.Oncology&Hematology AssociatePositionRockville,Maryland Competitive SalaryThis position offers a competitive base salary,a comprehensive benefits package,exceptional productivity incentives,and apartnership track.Hematology/Oncology-at th

7、e Beach inLow Tax Delaware!Delaware(US);Family-oriented resort area inbeautiful south coastal DelawareAbstractBRAF/MEK Targeting May YieldBenefit in Treating Biliary TractCancerBy Caroline Helwick,The ASCO Post,2019Efficacy,Safety,and CorrelativeBiomarkers of Toripalimab inPreviously Treated Recurre

8、nt orMetastatic NasopharyngealCarcinoma:A Phase II Clinical Trial(POLARIS-02)Feng-Hua Wang et al.,J Clin Oncol,2021BRAF/MEK Targeting May YieldBenefit in Treating Biliary TractCancerBy Caroline Helwick et al.,Hepatobiliary Cancer,2019bid D1-14,Q21d).The treatment continued untilthe disease progress

9、or having intolerable effects.The primary endpoints of the study wereprogression free survival(PFS)and overall survival(OS).The secondary endpoints were objectiveresponse rate(ORR),safety and treatmentbiomarkers.Results:At data cutoff(January 24,2021),fifty aBTC patients were enrolled atShanghai Zho

10、ngshan Hospital.Among thesepatients,56%are males.The median age of thestudy participants was 62 years of age.Themedian follow-up time was 10 months(rangedfrom 4 to 19 months).The primary tumor type wasintrahepatic cholangiocarcinoma(ICC)accountingfor 48%of total cases,followed by gallbladdercancer(G

11、BC)(40.0%),and extrahepaticcholangiocarcinoma(ECC)(12.0%).At the time ofdata collection,48 eligible patients were includedfor data analysis.The median PFS was 7.0 months（95%CI,5.5-9.1 months）and median OS was16.0 months(95%CI,12.1 to unreachable).TheORR was 27.1%and disease control rate was87.5%incl

12、uding 13 partial response(PR)and 29ADVERTISEMENTIntra-arterial hepatic chemotherapycombined with systemic infusion of5-FU in patients with advancedbiliary tract cancersA.Mambrini et al.,J Clin Oncol,2004Treatment of Inoperable and/orMetastatic Biliary Tree CarcinomasWith Single-Agent Gemcitabine or

13、inCombination With Levofolinic Acidand Infusional Fluorouracil:Resultsof a Multicenter Phase II StudyVittorio Gebbia et al.,J Clin Oncol,2016Systemic therapy for advancedcholangiocarcinoma:new options onthe horizonSaleh A.Alqahtani et al.,HepatomaResearch-OAE Publishing,2020Current and future drugco

14、mbination strategies based onprogrammed death-1/programmeddeath-ligand 1 inhibitors in non-small cell lung cancerYing Li Cheng et al.,Chinese MedicalJournal,2021CLINICAL EFFICACY OF CLADRIBINECOMBINED WITH RITUXIMAB INTREATMENT OF RECURRENT ORREFRACTORY MANTLE CELLLYMPHOMAWANG Yawen et al.,Journal o

15、fQingdao University(MedicalSciences),2019Durable ibrutinib responses inrelapsed/refractory marginal zonelymphoma:long-term follow-up andbiomarker analysisstable disease(SD)cases.The most treatmentrelated AEs(TRAE)were leukopenia(92.0%),anemia(86.0%)and rash(52.0%).Grade III/IV non-hematological TRAE

16、s were seen in 12 patients(24.0%),including rash(n=3),infection(n=6),immune-related colitis(n=1),immune-relatedpneumonitis(n=1)and mucositis(n=1).GradeIII/IV hematological TRAEs were seen in 62%patients.6 patients discontinued the study drugdue to TRAE.Serious adverse events(SAE)wereseen in 8 patien

17、ts and 2 patients died of biliaryobstruction complicated with infection.Forty-ninepatients were included in biomarker analysis.Themost mutated genes were TP53(51%),KRAS(20%),CDKN2A(18%)and SMAD4(16%).Patientswith activated PI3K signaling pathway hadsignificantly shorter PFS(P=0.026).Tumormutational

18、burden(TMB)could not serve as apredictor for the efficacy of immunotherapycombined with chemotherapy.Conclusions:Theclinical study of toripalimab combined withchemotherapy continued to show tolerance andefficacy in patients with aBTCs.Gene mutationAriela Noy et al.,Blood Advances,2020Randomized cont

19、rolled trial oficotinib concurrent with thoracicradiotherapy for treating advancednon-small cell lung cancer(NSCLC)Wang Jianfang et al.,Chinese Journalof Radiological Medicine andProtection,2017Powered byprofiling by NGS suggested mutated PI3K pathwaymight assocate with shorter PFS.Clinical trialinf

20、ormation:NCT03796429.2021 by American Society of Clinical OncologyResearch Sponsor:Shanghai Committee of Science and Technology,ChinaQUICK LINKSContentNewest Articles Archive Meeting AbstractsJournal InformationAbout Editorial Roster Contact Us PermissionsResourcesAuthors Reviewers Subscribers Insti

21、tutions AdvertisersSubmit Your ManuscriptSubscribe to this JournalASCO FAMILY OF SITESJournalsJournal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision OncologyPublicationsASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post E

22、ducationASCO eLearning ASCO Meetings Cancer.NetOther SitesASCO.org ASCO Author Services ASCO Career Center CancerLinQ Conquer Cancer Foundation TAPUR Study American Society of Clinical Oncology Terms of Use|Privacy Policy|Cookies2318 Mill Road,Suite 800,Alexandria,VA 22314 2021 American Society of Clinical Oncology